OVERVIEW OF ACTIVITY

Multiple myeloma (MM) accounted for 19,900 new cancer cases in the United States during 2007, with an estimated 10,790 deaths. The treatment of MM has improved dramatically over the past decade, particularly with the advent of novel agents, and the budding landscape surrounding the optimal treatment of MM is both exciting and complex. Knowledge of the many therapeutic advances and changing practice standards is essential to ensuring optimal patient outcomes. To bridge the gap between research and patient care, this CME activity utilizes the input of cancer experts and community physicians to frame a relevant discussion of recent research advances in myeloma that can be applied to routine clinical practice. This information will help medical oncologists, hematologists and hematology-oncology fellows formulate up-to-date clinical management strategies for patients.

LEARNING OBJECTIVES

• Appraise recent data on therapeutic advances and changing practice standards in MM, and apply this information to clinical practice.
• Manage patients with MM considering recent advances related to front-line therapy, treatment of relapsed or refractory disease, maintenance and salvage therapy and autologous stem cell transplantation (ASCT).
• Develop a treatment plan for patients with MM who have compromised renal function.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 4.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

To receive credit for this activity, the participant should read the print monograph and complete the Post-test and Educational Assessment and Credit Form located in the back of the monograph or on our website at ResearchToPractice.com/YearInReview. PowerPoint files of the graphics contained in this document can be downloaded at ResearchToPractice.com/YearInReview.

COMMERCIAL SUPPORT

This program is supported by an educational grant from Millennium Pharmaceuticals, The Takeda Oncology Company.

PHARMACEUTICAL AGENTS DISCUSSED IN THIS PROGRAM

This educational activity includes discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.